Aldosterone and diabetic kidney disease
- PMID: 19954691
- DOI: 10.1007/s11892-009-0074-x
Aldosterone and diabetic kidney disease
Abstract
Aldosterone plays an important role in salt and water homeostasis and blood pressure control through the classical mineralocorticoid receptor. However, recent findings of the mineralocorticoid receptor in nonepithelial tissues suggest that aldosterone may have additional functions. Significant evidence now exists suggesting that aldosterone directly induces tissue injury. Systemic or local aldosterone has emerged as a multifunctional hormone exhibiting profibrotic and proinflammatory actions that extend beyond the classical hemodynamic effect. The incomplete blockade of the renin-angiotensin-aldosterone system by angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers has led to experimental and clinical efforts using aldosterone inhibition. Recently, these efforts have provided us with an expanded understanding of a new pathogenic role for aldosterone in diabetic vascular complications. This article focuses on the role of aldosterone in the pathogenesis of diabetic kidney disease and recent important clinical data supporting the inhibition of aldosterone in treating diabetic kidney disease.
Similar articles
-
Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.Nephrology (Carlton). 2021 Nov;26(11):858-871. doi: 10.1111/nep.13917. Epub 2021 Jul 6. Nephrology (Carlton). 2021. PMID: 34176194 Review.
-
The role of aldosterone antagonism agents in diabetic kidney disease.J Ren Care. 2015 Mar;41(1):9-18. doi: 10.1111/jorc.12085. Epub 2014 Sep 15. J Ren Care. 2015. PMID: 25220494 Review.
-
The renin-angiotensin-aldosterone system blockade in patients with advanced diabetic kidney disease.Nefrologia (Engl Ed). 2018 Mar-Apr;38(2):197-206. doi: 10.1016/j.nefro.2017.07.003. Epub 2017 Nov 6. Nefrologia (Engl Ed). 2018. PMID: 29102270 English, Spanish.
-
Renoprotective Effects of Mineralocorticoid Receptor Antagonists Against Diabetic Kidney Disease.Adv Biol (Weinh). 2024 Mar;8(3):e2300496. doi: 10.1002/adbi.202300496. Epub 2023 Dec 8. Adv Biol (Weinh). 2024. PMID: 38065929 Review.
-
Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.Curr Opin Nephrol Hypertens. 2004 May;13(3):319-24. doi: 10.1097/00041552-200405000-00009. Curr Opin Nephrol Hypertens. 2004. PMID: 15073491 Review.
Cited by
-
Molecular Mechanisms of Diabetic Kidney Disease.Int J Mol Sci. 2022 Aug 4;23(15):8668. doi: 10.3390/ijms23158668. Int J Mol Sci. 2022. PMID: 35955802 Free PMC article. Review.
-
Potential of Renin-Angiotensin-Aldosterone System Modulations in Diabetic Kidney Disease: Old Players to New Hope!Rev Physiol Biochem Pharmacol. 2021;179:31-71. doi: 10.1007/112_2020_50. Rev Physiol Biochem Pharmacol. 2021. PMID: 32979084 Review.
-
Efficacy and Safety of Non-Steroidal Mineralocorticoid Receptor Antagonists in Patients With Chronic Kidney Disease and Type 2 Diabetes: A Systematic Review Incorporating an Indirect Comparisons Meta-Analysis.Front Pharmacol. 2022 Jun 16;13:896947. doi: 10.3389/fphar.2022.896947. eCollection 2022. Front Pharmacol. 2022. PMID: 35784710 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical